Hero background


CellSight is dedicated to advancing and disseminating knowledge that propels us to share our findings openly and transparently. Through our commitment to research and innovation, we strive to contribute to the collective pool of knowledge, foster collaboration, and drive progress in our field.


SNMMI 2024 Toronto
Levi J. |June 10th, 2024
Simultaneous imaging of activated lymphocytes and adipocytes with [18F]F-AraG reveals association between neuroinflammation and brown- and bone marrow adipose tissue
SNMMI 2024 Toronto
Nobashi T.|June 9th, 2024
Psyhological Uptake of 18F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan.
Immunology 2024 Chicago
Chae H-D.|May 5th, 2024
Emergence of novel CD3+ Macrophages in Brown Adipose Tissue Following Adrenergic Stimulation
EMIM 2024 Porto
Guglielmetti C.|March 15th, 2024
18F-AraG PET imaging of activated T cells differentiates between acute and chronic lesions in a multiple sclerosis model
EMIM 2024 Porto
Wijngaarden J.E.|March 15th, 2024
Pharmacokinetic analysis and simplified uptake measures for tumor lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
EMIM 2024 Porto
Levi J.|March 13th, 2024
18F-AraG Accumulates in Metabolically Active Brown- and Bone Marrow Adipose Tissue See more section
CROI 2024 Colorado
Henrich T.|March 4th, 2024
[18F]F-AraG PET Imaging Reveals Unique Tissue T Cell Activation Patterns Across HIV Infection States
SNNMI 2023 Chicago
Shrestha U. |January 1st, 2023
A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity.
iSRS 2023 Hawaii
Blecha J.|January 1st, 2023
Synthesis of [18F]F-AraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms.